Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.
Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.
复制标题
DOI：
10.2217/thy.10.84
复制
发表时间：
2011-01
期刊：
影响因子：
--
通讯作者：
Raez LE
中科院分区：
文献类型：
--
作者：
Holt GE;Podack ER;Raez LE
积极调节患者的免疫系统以产生抗肿瘤免疫是一种有吸引力的策略，可以改善通常与非小细胞肺癌（NSCLC）相关的令人沮丧的结果。使用增强特异性抗肿瘤免疫力或积极影响患者免疫系统的方法，以允许从头产生免疫力，以涵盖最近NSCLC临床试验中使用的当前策略。抗原特异性免疫疗法的II期试验的令人鼓舞的结果导致了随后的三项III期试验，目前正在招募。这些试验的结果将提高我们对免疫疗法在NSCLC治疗中所起作用的理解。体液疫苗在古巴的成功应用导致其在该国被批准用于治疗晚期NSCLC患者。迄今为止，涉及非特异性免疫干预的试验未能改善NSCLC的结局，可能表明需要将其与抗原特异性疫苗联合使用。虽然这些试验将大大提高我们对NSCLC免疫治疗的认识，但我们认为，真正有效的免疫治疗可能只会产生于增强抗肿瘤免疫力和对抗肿瘤介导的免疫抑制的策略的实施。
Positive modulation of a patient’s immune system to produce antitumor immunity is an attractive strategy that may improve the dismal outcomes typically associated with non-small-cell lung cancer (NSCLC). Using methods that either augment specific antitumor immunity or positively influence the patient’s immune system to allow the de novo generation of immunity to encompass current strategies used in recent clinical trials of NSCLC. Encouraging results of Phase II trials in antigen-specific immunotherapy have led to three subsequent Phase III trials, which are currently enrolling. Results of these trials will improve our understanding of the role that immunotherapy plays in the treatment of NSCLC. Successful application of a humoral vaccine in Cuba led to its approval for the treatment of advanced NSCLC patients in that country. To date, trials involving nonspecific immunotherapeutic interventions have failed to improve outcomes in NSCLC and may indicate a need to combine them with antigen-specific vaccines. Although these trials will greatly advance our knowledge of NSCLC immunotherapy, we believe truly efficacious immunotherapy may only result from implementation of strategies to both augment antitumor immunity and counteract tumor-mediated immunosuppression.